Evidence map›Paper›PMID 19371746›Full record

ArticleJournal of molecular and cellular cardiology2009

Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine.

N Lindegger, B M Hagen, A R Marks, W J Lederer, R S Kass

Registry-linked trialAbstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01728025 (Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01728025 phase2unknown statusnot on this mapstarted 2012, after this paper: background citation

Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

TypeinterventionalSponsorTel-Aviv Sourasky Medical CenterRan2012 to 2017Enrolled10ConditionsLong QT Syndrome Type 3ArmsRanolazine
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Review
  5. Activation of small conductance CaThe Journal of physiology · 2023
    Article
  6. Review
  7. Review
  8. A novel substrate for arrhythmias in Chagas disease.PLoS neglected tropical diseases · 2021
    Article
  9. Article
  10. Review
  11. Review
  12. Ion channels, long QT syndrome and arrhythmogenesis in ageing.Clinical and experimental pharmacology & physiology · 2017
    Review
  13. Review
  14. Review
  15. Ranolazine is an Effective and Safe Treatment of Adults with Symptomatic Premature Ventricular Contractions due to Triggered Ectopy.The International journal of angiology : official publication of the International College of Angiology, Inc · 2016
    Article
  16. Ranolazine for the suppression of ventricular arrhythmia: a case series.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2014
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

N LindeggerDepartment of Pharmacology, Columbia University College of Physicians and Surgeons, 630 West 168th St., New York, NY 10032, USA.
B M Hagen
A R Marks
W J Lederer
R S Kass
Columbia University · USBiotechnology Institute · USUniversity of Maryland, Baltimore · US

Funding

Molecular Basis of Sudden Cardiac DeathP01HL067849 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MARKS, ANDREW ROBERT · 2001 to 2011
$15.0M
MOLECULAR PHARMACOLOGY OF AN INHERITED HEART DISEASER01HL056810 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KASS, ROBERT S · 1998 to 2011
$4.0M
NHLBI NIH HHS 5R01 HL0 56810-15NHLBI NIH HHS P01 HL067849NHLBI NIH HHS P01 HL076849-07
6 · The paper itself

Abstract

Long QT syndrome variant 3 (LQT-3) is a channelopathy in which mutations in SCN5A, the gene coding for the primary heart Na(+) channel alpha subunit, disrupt inactivation to elevate the risk of mutation carriers for arrhythmias that are thought to be calcium (Ca(2+))-dependent. Spontaneous arrhythmogenic diastolic activity has been reported in myocytes isolated from mice harboring the well-characterized Delta KPQ LQT-3 mutation but the link to altered Ca(2+) cycling related to mutant Na(+) channel activity has not previously been demonstrated. Here we have investigated the relationship between elevated sarcoplasmic reticulum (SR) Ca(2+) load and induction of spontaneous diastolic inward current (I(TI)) in myocytes expressing Delta KPQ Na(+) channels, and tested the sensitivity of both to the antianginal compound ranolazine. We combined whole-cell patch clamp measurements, imaging of intracellular Ca(2+), and measurement of SR Ca(2+) content using a caffeine dump methodology. We compared the Ca(2+) content of Delta KPQ(+/-) myocytes displaying I(TI) to those without spontaneous diastolic activity and found that I(TI) induction correlates with higher sarcoplasmic reticulum (SR) Ca(2+). Both spontaneous diastolic I(TI) and underlying Ca(2+) waves are inhibited by ranolazine at concentrations that preferentially target I(NaL) during prolonged depolarization. Furthermore, ranolazine I(TI) inhibition is accompanied by a small but significant decrease in SR Ca(2+) content. Our results provide the first direct evidence that induction of diastolic transient inward current (I(TI)) in Delta KPQ(+/-) myocytes occurs under conditions of elevated SR Ca(2+) load.

Indexed as

AcetanilidesAnimalsCalciumCalcium SignalingDiastoleDose-Response Relationship, DrugIon Channel GatingLong QT SyndromeMiceMutationMyocytes, CardiacPiperazinesRanolazineAcetanilidesCalciumPiperazinesRanolazine

Identifiers

PMID19371746
PMCPMC2703681
OpenAlexW2034233911

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.